Bio-Rad Laboratories Peer Comparison

$379.50

$0.00 (0.00%)

As on 06-Nov-2026 09:30EST

Market cap

$10,147 Mln

Revenue (TTM)

$2,593 Mln

P/E Ratio

10.1

P/B Ratio

1.4

Div. Yield

0 %

Edit

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Market cap ($ Mln)	10,147	13,022	12,656	11,090	10,259
Revenue ($ Mln)	2,593	690	1,560	806	6,636
Net Profit ($ Mln)	1,022.90	-169.80	157.02	-11.80	337.20
Net Margin (%)	39.45	-24.60	10.06	-1.47	5.08
RoE (%)	14.15	-24.46	10.27	-0.56	5.90
Price to Earnings	10.08	--	80.88	--	31.54
Price-To-Book	1.41	18.16	8.03	5.30	1.81

Income Statement ($ Mln)

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Operating Revenue	2,592.70	690.33	1,560.33	805.61	6,635.60
Cost of Revenue	1,263.70	130.29	499.55	394.34	4,539.20
Gross Profit	1,343.60	393.22	942.44	347.62	2,139.40
Operating Expenses	1,209.10	623.34	871.54	392.34	1,593.70
Operating Profit (EBIT)	118.90	-63.30	189.25	18.93	502.70
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	1,320.20	-174.52	207.82	8.23	315.50
Provision for Tax	297.30	-4.72	50.81	20.03	-21.70
Profit after Tax (Net Income)	1,022.90	-169.80	157.02	-11.80	337.20
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	47.34	0.00	0.00

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Shareholder's Funds	7,603.00	717.27	1,583.51	2,091.74	5,835.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	2,211.00	135.53	207.78	708.99	4,425.10
Current Liabilities	969.10	126.73	233.81	125.69	1,369.00
Total Liabilities	10,576.50	893.49	1,826.52	2,949.70	11,794.70

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Non-Current Assets	7,704.50	399.88	648.47	1,684.42	9,037.40
Current Assets	3,078.60	579.65	1,376.63	1,241.98	2,592.60
Total Assets	10,576.50	893.49	1,826.52	2,949.70	11,794.70
Total Debt*	1,363.40	101.98	209.39	692.24	3,683.80
Net Current Assets	2,109.50	452.92	1,142.82	0.00	1,223.60

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Cash From Operating Activities	532.20	-46.34	238.66	117.42	623.80
Cash Flow from Investing Activities	-189.70	-77.61	-404.59	-298.47	-130.50
Cash from Financing Activities	-283.20	11.89	26.53	-15.21	-409.40
Net Cash Inflow / Outflow	--	--	--	--	--

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
ROCE (%)	8.98	-22.53	11.76	1.79	-5.43
ROE (%)	14.15	-24.46	10.27	-0.56	5.90
ROA (%)	9.31	-15.48	7.53	-0.33	2.57
EBIT Margin (%)	52.80	-24.51	13.40	4.20	7.39
Net Margin (%)	39.45	-24.60	10.06	-1.47	5.08
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Revenue Growth (%)	1.38	46.94	16.98	13.80	0.92
EBIT Growth (%)	272.53	-106.70	11.72	29.47	106.97
Net Profit Growth (%)	251.34	-93.80	-4.27	-779.17	510.22
EPS Growth (%)	256.24	-90.00	-4.95	-910.66	507.22
Book Value Growth (%)	12.77	-12.58	15.61	0.35	4.89

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Price / Earnings	--	-34.59	68.93	189.42	-14.68
Price / Book Value	--	18.16	8.03	4.40	1.81
Dividend Yield (%)	--	0.00	0.00	--	0.00
EV/EBITDA	--	-103.90	53.80	50.32	15.22
Market Cap ($ Cr)	--	--	--	--	--

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Debt to Equity	0.11	0.00	0.00	0.00	0.63
Short term debt to equity ratio	0.06	0.00	0.01	0.01	0.01
Current Ratio	3.18	4.57	5.89	9.88	1.89
Quick Ratio	2.37	4.09	3.92	8.43	1.27
Interest Coverage	28.05	-35.23	165.16	1.24	2.81

	Bio-Rad Laboratories	Glaukos Corp (GKOS)	Penumbra (PEN)	Repligen (RGEN)	Avantor (AVTR)
Debtors to sales (%)	16.30	21.73	12.51	18.77	16.92
Asset Turnover	0.24	0.63	0.75	0.22	0.51
Receivable days	65.39	60.95	46.54	72.41	58.79
Inventory Days	221.09	193.84	331.92	146.53	64.13
Payable days	37.02	60.19	26.16	29.05	58.13
Cash Conversion Cycle	249.46	194.60	352.30	189.88	64.79

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.